| 主权项 |
1. A method of treating an NK1 receptor mediated disease comprising:
administering to a patient in need thereof an oral dosage form comprising an effective amount of at least one compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are selected from the group consisting of alkyl, haloalkyl, alkyl substituted with one or more hydroxyl groups, —CN, alkynyl, —N(R6)2, —N(R6)—S(O2)-alkyl, —N(R6)—C(O)—N(R9)2, -alkylene-CN, -cycloalkylene-CN, -alkylene-O-alkyl, —C(O)-alkyl, —C(═N—OR5)-alkyl, —C(O)—O-alkyl, -alkylene-C(O)-alkyl, -alkylene-C(O)—O-alkyl, -alkylene-C(O)—N(R9)2, with the proviso that at least one of R1 and R2 is —CN, W is ═C(R8)— or ═N—; X is —C(O)— or —S(O2)—; Y is selected from the group consisting of —CH2—, —O—, and —N(R6)—C(O)—, with the proviso that: (a) the nitrogen atom of —N(R6)—C(O)— is bonded to X, and (b) if R1 and/or R2 is and Y is —O—, X is not —S(O2)—; Z is —C(R7)2, —N(R6)—, or —O—; R3 is selected from the group consisting of H, and unsubstituted alkyl; R4 is H; R5 is H or alkyl; R6 is selected from the group consisting of H, alkyl, cycloalkyl, and aryl; R8 is selected from the group consisting of H, alkyl, cycloalkyl, and aryl; each R7 is independently H or alkyl; or
each R7, together with the ring carbon to which they are shown attached, form a cycloalkylene ring; R8 is selected from the group consisting of H, alkyl, alkyl substituted with one or more hydroxyl groups, —N(R6)2, —N(R6)—S(O2)-alkyl, —N(R6)—S(O2)-aryl, —N(R6)—C(O)-alkyl, —N(R6)—C(O)-aryl, alkylene-O-alkyl, and —CN; R9 is selected from the group consisting of H, alkyl, and aryl, or each R9, together with the nitrogen to which they are shown attached, form a heterocycloalkyl ring; Ar1 is unsubstituted phenyl; Ar2 is phenyl substituted with 0-3 substituents selected from the group consisting of haloalkyl; n is 0, 1, or 2; and m is 1, 2 or 3.
|
